ČEŠKOVÁ, Eva. Postavení aripiprazolu v klinické praxi (Position of aripiprazole in clinical practice). Česká a slovenská psychiatrie. Praha: ČLS JEP, 2011, vol. 107, No 2, p. 110-114. ISSN 1212-0383. |
Other formats:
BibTeX
LaTeX
RIS
|
Basic information | |
---|---|
Original name | Postavení aripiprazolu v klinické praxi |
Name in Czech | Postavení aripiprazolu v klinické praxi |
Name (in English) | Position of aripiprazole in clinical practice |
Authors | ČEŠKOVÁ, Eva. |
Edition | Česká a slovenská psychiatrie, Praha, ČLS JEP, 2011, 1212-0383. |
Other information | |
---|---|
Original language | Czech |
Type of outcome | Article in a journal |
Field of Study | 30000 3. Medical and Health Sciences |
Country of publisher | Czech Republic |
Confidentiality degree | is not subject to a state or trade secret |
Organization unit | Central European Institute of Technology |
Keywords (in Czech) | aripiprazol; účinnost; snášenlivost; schizofrenní porucha; afektivní porucha; monoterapie; augmentace |
Keywords in English | aripiprazole; efficacy; tolerability; schizofrenic disorder; affective disorder; monotherapy; augmentation |
Changed by | Changed by: prof. MUDr. Eva Češková, CSc., učo 726. Changed: 20/5/2011 13:02. |
Abstract |
---|
Antipsychotika 2. generace jsou rozšiřována i do oblasti afektivních poruch, hlavně BP. Aripiprazol rozšiřuje spektrum AP 2. generace. Z hlediska účinnosti je spíše aktivující, a tedy vhodný tam, kde nemocnému vadí sedace. U BP se řadí k AP, jejichž efekt se týká hlavně manické komponenty. U farmakorezistentní deprese dále rozšiřuje prokazatelně účinné augmentační strategie. Z praktického hlediska je velkou výhodou minimální spojední s přírůstkem hmotnosti a metabolickými nežádoucími účinky. |
Abstract (in English) |
---|
Data about efficacy of aripiprazole in the treatment of schizophrenic and bipolar disorder are summarized. In schizophrenia aripiprazole represents a common strategy in patients with sedation and weight increase on the present treatment. In bipolar disorder aripiprazole belongs to antipsychotics of the second generation influencing mostly the manic component of the disorder. Undoubtedly it is iteresting, that aripiprazole like others antipsychotics represents a successful augmentation in pharmacoresistant depression. An advantage is the different profile of adverse events. Aripiprazole is minimally associated with weight increase and metabolic adverse events. It represents a justified enlargement of possibilities of individualized treatment, which is considered to be an optimal strategy in the treatment of severe psychic disorders. |
Links | |
---|---|
MSM0021622404, plan (intention) | Name: Vnitřní organizace a neurobiologické mechanismy funkčních systémů CNS |
Investor: Ministry of Education, Youth and Sports of the CR, The internal organisation and neurobiological mechanisms of functional CNS systems under normal and pathological conditions. |
PrintDisplayed: 18/10/2024 03:07